Open AccessDNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a C hinese population
Author(s) -
Yu Xian,
Xiao He,
Zhao Baojian,
Zhang Xu,
Wang Ge
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12251
Subject(s) - ercc1 , medicine , xrcc1 , gastroenterology , odds ratio , confidence interval , oncology , nucleotide excision repair , genotype , dna repair , single nucleotide polymorphism , gene , biology , genetics
Background DNA repair gene polymorphisms could alter DNA repair capacity and therefore associate with tumor sensitivity to radiochemotherapy. This study assessed excision repair cross‐complementing group 1 ( ERCC1) C118T and X‐ray cross‐complementing group 1 ( XRCC1) G399A single‐nucleotide polymorphisms in esophageal patients for an association with sensitivity to radiation and chemotherapy. Methods Esophageal squamous cell carcinoma patients ( n = 118) who relapsed after surgery were enrolled for assessment of ERCC1 C118T and XRCC1 G399A polymorphisms by direct DNA sequencing. Results The response rate of treatments was 48.30%: 14 complete response ( CR, 11.86%), 43 partial response ( PR , 36.44%), 49 stable disease ( SD, 41.53%), and 12 progressive disease ( PD, 10.17%). ERCC1 C118T was significantly associated with treatment response ( C/T vs. C / C + T/T , odds ratio [ OR] = 6.035, 95% confidence interval [ CI] : 2.114–17.226, P = 0.001) after adjusting for other clinicopathological factors. Patients carrying the C/T genotype had significantly prolonged overall survival ( OS) compared with C / C and T/T (median OS 43.00 vs. 27.00, P = 0.027). Multivariate Cox regression showed that a response was only an independent prognostic factor for OS ( CR + PR vs. SD + PD, HR = 0.471 95% CI 0.269–0.826, P = 0.009). Grade III and IV adverse events occurred in 12 of 118 patients (10.17%). Only concurrent radiochemotherapy significantly increased these adverse events ( OR = 26.529, 95% CI 2.312–304.389, P = 0.008). Conclusion ERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.